ACRV · Acrivon Therapeutics, Inc. · Executive Compensation
Market Cap
$72.60M
Shares
42.85M
Volume · Oct 20
67.89K
Avg daily vol (3M)
316.11K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Peter Blume-Jensen | M.D., Ph.D. Chief Executive Officer, President and Director | $2,718,538 |
| Kristina Masson | Ph.D, M.B.A. Executive Vice President, Business Operations, Director | $1,424,926 |
| Eric Devroe | Chief Operating Officer | $1,358,003 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Peter Blume-Jensen | M.D., Ph.D. Chief Executive Officer, President and Director | $2,000,312 |
| Kristina Masson | M.B.A., Ph.D. Executive Vice President, Business Operations, Director | $1,197,176 |
| Eric Devroe | Chief Operating Officer | $1,146,728 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Peter Blume-Jensen | M.D., Ph.D. Chief Executive Officer, President and Director | $6,465,973 |
| Kristina Masson | M.B.A., Ph.D. Executive Vice President, Business Operations, Director | $739,783 |
| Eric Devroe | Chief Operating Officer | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Peter Blume-Jensen | M.D., Ph.D. Chief Executive Officer, President and Director | $21,685,240 |
| Eric Devroe | Chief Operating Officer | $2,179,897 |
| Rasmus Holm-Jorgensen | Chief Financial Officer | $1,720,908 |
| Mary-Alice Miller | Chief Legal Officer | — |
| Kristina Masson | M.B.A., Ph.D. Executive Vice President, Business Operations, Director | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Peter Blume-Jensen | M.D., Ph.D. Chief Executive Officer, President and Director | $756,771 |
| Eric Devroe | Chief Operating Officer | $462,939 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Charles Baum, M.D., Ph.D. | Class I Director | Appointed | 2026-06-17 |
| Michael Tomsicek, M.B.A. | Class I Director | Appointed | 2026-06-17 |
| Adam Levy, Ph.D., M.B.A. | Principal Financial Officer | Appointed | 2025-03-14 |
| Adam Levy, Ph.D., M.B.A. | Chief Financial Officer | Appointed | 2025-03-14 |
| Santhosh Palani, Ph.D., CFA | director | Appointed | 2024-03-04 |
| Ivana Magovcevic-Liebisch, Ph.D., J.D. | director | Appointed | 2024-02-08 |
Leadership
- Peter Blume-Jensen CEO
- Adam Levy CFO
- Adam Levy, Ph.D., M.B.A. CFO
- Eric Devroe COO
- Charles Baum, M.D., Ph.D. Board Member
- Ivana Magovcevic-Liebisch, Ph.D., J.D. Board Member
- Kristina Masson Board Member
- Michael Tomsicek, M.B.A. Board Member
- Santhosh Palani, Ph.D., CFA Board Member